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Abstract
Background: In 2012, the World Health Organization recommended blocking the transmission of Plasmodium
falciparum with single low-dose primaquine (SLDPQ, target dose 0.25 mg base/kg body weight), without
testing for glucose-6-phosphate dehydrogenase deficiency (G6PDd), when treating patients with uncomplicated
falciparum malaria. We sought to develop an age-based SLDPQ regimen that would be suitable for sub-Saharan Africa.
Methods: Using data on the anti-infectivity efficacy and tolerability of primaquine (PQ), the epidemiology of anaemia,
and the risks of PQ-induced acute haemolytic anaemia (AHA) and clinically significant anaemia (CSA), we prospectively
defined therapeutic-dose ranges of 0.15–0.4 mg PQ base/kg for children aged 1–5 years and 0.15–0.5 mg PQ base/kg
for individuals aged ≥6 years (therapeutic indices 2.7 and 3.3, respectively). We chose 1.25 mg PQ base for infants aged
6–11 months because they have the highest rate of baseline anaemia and the highest risks of AHA and CSA. We
modelled an anthropometric database of 661,979 African individuals aged ≥6 months (549,127 healthy individuals,
28,466 malaria patients and 84,386 individuals with other infections/illnesses) by the Box–Cox transformation power
exponential and tested PQ doses of 1–15 mg base, selecting dosing groups based on calculated mg/kg PQ doses.
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Results: From the Box–Cox transformation power exponential model, five age categories were selected: (i) 6–11 months
(n = 39,886, 6.03%), (ii) 1–5 years (n = 261,036, 45.46%), (iii) 6–9 years (n = 20,770, 3.14%), (iv) 10–14 years (n = 12,155, 1.84%)
and (v) ≥15 years (n = 328,132, 49.57%) to receive 1.25, 2.5, 5, 7.5 and 15 mg PQ base for corresponding median (1st and
99th centiles) mg/kg PQ base of: (i) 0.16 (0.12–0.25), (ii) 0.21 (0.13–0.37), (iii) 0.25 (0.16–0.38), (iv) 0.26 (0.15–0.38) and (v) 0.27
(0.17–0.40). The proportions of individuals predicted to receive optimal therapeutic PQ doses were: 73.2 (29,180/39,886),
93.7 (244,537/261,036), 99.6 (20,690/20,770), 99.4 (12,086/12,155) and 99.8% (327,620/328,132), respectively.
Conclusions: We plan to test the safety of this age-based dosing regimen in a large randomised placebo-controlled trial
(ISRCTN11594437) of uncomplicated falciparum malaria in G6PDd African children aged 0.5− 11 years. If the regimen is
safe and demonstrates adequate pharmacokinetics, it should be used to support malaria elimination.
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Background
In an effort to stem the continuing emergence of
artemisinin-resistant Plasmodium falciparum (ARPf)
from the Greater Mekong Subregion to other parts of the
world [1–8], the World Health Organization (WHO) has
recommended the addition of single low-dose primaquine
(SLDPQ) to artemisinin-based combination therapy
(ACTs) for treating acute uncomplicated falciparum mal-
aria in low-transmission areas, particularly where ARPf is
prevalent [9, 10]. The recommended target dose of 0.25
mg/kg body weight of PQ base was considered safe, even
in patients with severe forms of glucose-6-phosphate de-
hydrogenase deficiency (G6PDd). Accordingly, the WHO
recommended its adoption without G6PDd testing.
While SLDPQ is not currently deployed anywhere in
sub-Saharan African (SSA), several low-endemicity coun-
tries, including Botswana, Eritrea, Swaziland and Zimbabwe
(R. Cibulski, personal communication) have added SLDPQ
to their national treatment guidelines and intend to go for-
ward with SLDPQ treatment. The main reasons cited by
ministries of health for not enacting the WHO recommen-
dation is the fear that SLDPQ would cause acute haemo-
lytic anaemia (AHA) in G6PDd individuals and the
impossibility of widely deploying a suitable G6PDd test to
exclude such individuals from receiving SLDPQ [11].
Despite this, there is an increasing body of evidence
that SLDPQ is tolerated well by both malaria patients
and healthy individuals with good pre-treatment
haemoglobin (Hb) concentrations in both Southeast
Asia [12] and SSA [13] (SAFEPRIM I and II, and
PQSAFETY studies; ClinicalTrials.gov identifiers
NCT02174900, NCT02654730, and NCT02535767).
Moreover, pilot work has demonstrated the feasibility
of deploying SLDPQ in Swaziland’s health system
[14].
Important hurdles to using SLDPQ include the lack
both of user-friendly age- or weight-based regimens and
of suitable paediatric formulations and tablet strengths
that have been produced to good manufacturing practice
standards and registered to international standards.
Although the WHO did recommend a weight-based
dose regimen in 2015, it relies on tablet fractions [15].
We recently designed an age-based dosing regimen for
Cambodia (and by extension several neighbouring coun-
tries) using four tablet strengths: 2.5, 5, 7.5 and 15 mg
[16]. This regimen resulted in high proportions of patients
who would receive an optimised transmission-blocking
PQ dose, defined as 0.15–0.38 mg/kg body weight of PQ
base, taking into account that the severe G6PDd Viang-
chan variant is prevalent in Cambodia [17, 18].
Age-based dosing regimens exist for several anti-
malarial drugs, including artesunate (AS)-mefloquine
and AS-amodiaquine (AQ; ASAQ) [19]. They offer
the substantial advantage of not requiring weighing
scales and are suitable for the rapid distribution of drugs
to large numbers of individuals, even under logistically
challenging circumstances, for example, the mass drug ad-
ministration (MDA) of ASAQ in Liberia during a recent
Ebola outbreak [20]. Moreover, several SSA countries have
adopted home-based management of malaria [21] and
many patients buy their drugs from the informal private
sector, where reliable weighing scales may not be available
[22–25].
The development of an age-based dosing regimen
requires a thorough examination of efficacy, tolerabil-
ity, pharmacokinetics (PK), PK–pharmacodynamic
(PD; PKPD) relationships, regimen simplicity, and
suitable tablet strength availability. These aspects have
been investigated elsewhere [16], but a recent study
of PQ PK in P. falciparum-infected children aged
2–14 years from Burkina Faso illustrates the inde-
pendent effects of age, weight and cytochrome 2D6
metaboliser status on PQ and carboxyPQ exposures
[26]. Younger children and children with a lower
body weight had lower PQ and carboxyPQ exposures,
and poor PQ metabolisers had increased PQ but re-
duced carboxyPQ exposures. In this paper, we review
aspects of SLDPQ pertinent to SSA and discuss how
we determined our proposed age-based dosing regi-
men for SLDPQ.
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Low-dose primaquine efficacy in reducing mosquito
infectivity
Early work demonstrated a rapid reduction in mosquito
infectivity (within 15 hours) when low doses (e.g. 10 mg)
of the 8-aminoquinoline pamaquine/plasmoquine were
combined with standard antimalarial treatments in falcip-
arum malaria patients [27, 28]. Later work suggested that
15 mg of PQ had a similar effect on mosquito infectivity
as 45 mg (0.75 mg/kg in a 60-kg adult) [29, 30].
The comprehensive effect of SLDPQ on mosquito
infectivity has been demonstrated by Dicko et al., who
studied symptomatic [12/81 (14.8%)] and asymptomatic P.
falciparum-infected Malian adults and children with ≥2
gametocytes on a thick blood film [31]. Given with the
first dose of dihydroartemisinin-piperaquine (DHAPP),
the mg/kg dose of PQ base was 0 (control), 0.0625, 0.125,
0.25 and 0.5. Efficacy was assessed by direct mosquito
membrane feeding assays.
The primary efficacy endpoint was the mean within-
person percentage reduction in mosquito infectivity for
a given PQ-dosing group on study day 2 (D2), i.e.
48 hours in patients infected ≥1 mosquito pre- and post-
PQ treatment:
100% × (N infected individuals at D0 – N infected indi-
viduals at D2)/N infected individuals at D0.
The 0.125-mg/kg dose (7.5 mg in a 60-kg individual)
achieved a mean 94.9% [95% confidence interval (CI)
84.6–100] reduction in infectivity (p = 0.045) whereas
the 0.0625-mg/kg dose (3.75 mg in a 60-kg individual)
achieved a non-significant 59.83% reduction in infectiv-
ity (95% CI 16.9–100, p = 0.18). Consistent results come
from a dose-ranging study in DHAPP-dosed Cambodian
and Vietnamese P. falciparum-infected adults. A signifi-
cant anti-infectivity effect was seen with 3.75 mg of PQ
base and a maximal blocking effect was seen with
7.5 mg of PQ base [9].
Dicko et al. reconfirmed the pre-treatment non-linear
gametocyte density–infectivity relationship [32–34], but fol-
lowing treatment there was no relationship between gam-
etocyte density and mosquito infectivity. Consistent with
these observations are the findings that febrile adults with
patent gametocytaemia are more infectious than those who
are afebrile with subpatent gametocytaemia [35], and that
asymptomatic P. falciparum carriers (QT-NASBA-positive
gametocytaemia) have low baseline [36] and post-treatment
[artemether-lumefantrine (AL) or DHAPP] infectivity
whether or not they also received SLDPQ [36, 37].
Based on the patient mosquito infectivity data, we
chose the same minimum 0.15 mg/kg dose of PQ base
as we did in Cambodia [16].
Primaquine tolerability and safety
PQ is a well-tolerated and very safe drug. The mortality
associated with PQ has been estimated at only 1 in
621,428 (upper 95% CI 1 in 407,807) patients treated,
most having been associated with repeated PQ dosing as
anti-relapse therapy for vivax malaria [38]. The three
principal side effects of PQ, all dose-dependent, are ab-
dominal pain, methaemoglobinaemia and AHA.
Gastrointestinal side effects
Occurrences of abdominal pain and vomiting have been
unremarkable in recent trials in asymptomatic P. falcip-
arum-infected African children, dosed with PQ on D2.
PQ-induced abdominal pain and early vomiting necessi-
tating retreatment were not reported by Goncalves et al.
[36] or Eziefula et al. [39], but the former re-dosed 5/360
patients with AL on D0 or D1. Okebe et al. re-dosed 1/
344 children with DHAPP and the reported frequencies of
abdominal pain in the DHAPP-alone vs. DHAPP + PQ
arms (0.2, 0.4 and 0.75 mg/kg) were 12, 14, 15 and 9%,
respectively [37].
Similarly, 14 (2.5%) of 564 children treated with
sulphadoxine-pyrimethamine (SP), artesunate and PQ on
D2 vomited but none had persistent vomiting following
retreatment [40]. Dicko et al. reported overall rates of mild
abdominal pain of 10% and mild vomiting of 1.3% across
all arms but no one required repeat dosing [31] whilst
acutely infected falciparum patients of all ages (median
10 years) from Tanzania had identical rates of abdominal
pain and vomiting of 6.4% (7/110) and 5.5% (6/110), re-
spectively, in the AL-alone and the AL + SLDPQ arms [13].
When ACTs are given alone, early ACT-induced vomit-
ing in uncomplicated malaria patients occurs primarily in
children aged <5 years and, within this age band, the
youngest children are at the highest risk. Rates of early
vomiting tend to be significantly less frequent on D1 com-
pared to D0. DHAPP is associated with the highest D0
rate of early vomiting (7–10%) whilst AL and ASAQ have
overlapping rates (<3–6%) [41–44]. One trial reported
very low early vomiting rates in adults and children aged
>5 years: 0.4% (2/496) vs. 0% (0/502) in ASAQ (mean age
17.3 years) and AL-treated patients (mean age 16.5 years),
respectively [44]. The WHO recommendation is to give
SLDPQ with the first dose of ACT. Whether this would
increase the rates of early vomiting in younger children,
who, therefore, might be better dosed on D1 due to better
tolerability, is unknown.
Methaemoglobinaemia
While no published PQ studies from Africa have mea-
sured methaemoglobin (metHb) concentrations, they are
being measured in an ongoing study (ClinicalTrials.gov
identifier NCT02535767). Methaemoglobinaemia mani-
fests clinically as a blue discoloration of the lips and
tongue when metHb concentrations are approximately
20%. metHb levels are mildly raised in malaria and correl-
ate positively with disease severity. Mean levels of 2%,
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4.1% and 5.8% were reported in healthy controls, uncom-
plicated malaria patients and severe malaria patients with
death or clinical sequelae, respectively [45]. Data from
Cambodia show that 0.25 mg/kg of PQ (L. Desoley, un-
published) in P. falciparum-infected patients and 0.75 mg/
kg in P. vivax-infected patients resulted in a maximum
metHb concentration of 3.6% and 4.9% [46], respectively.
Thus, methaemoglobinaemia is not considered a clinical
concern in SLDPQ-treated African children.
Acute haemolytic anaemia and African variants of G6PD
deficiency
The most-feared PQ side effect is dose-related AHA.
Previous experience with AHA induced by chlorprogua-
nil dapsone, resulting in the stopping of its development,
is a cautionary lesson [47, 48]. The incidence of AHA
is greater in individuals with lower G6PD enzyme ac-
tivities, so that hemizygous males and homozygous fe-
males are more likely to suffer PQ-induced AHA
than heterozygous females with intermediate G6PD
enzyme activities [49, 50].
The G6PDd A- variant (G202A), which in one study
from Kenya accounted for most of the variance in G6PD
enzyme activity [51], is the most common G6PD variant in
SSA [52], with reported allele frequencies of ~2% in The
Gambia, ~17% in Kenya and ~21% in Nigeria [53–55]. Al-
though referred to as a mild variant, enzyme activities of ≤1
U/g Hb are well documented [56–58]. Other mild A- vari-
ants, reported from West Africa are G6PDd Mexico City
(C680A) and Betica-Selma (A968G) [59].
G6PD Santamaria (T542A), a severe G6PDd variant, is
also present in West Africa [59] and has a residual en-
zyme activity of ~2–3% of wild-type G6PD [60, 61]. It
had a reported allele frequency of 6.6% in 2379 Gambian
children [62]. In Sudan, the frequencies in males of the
severe G6PD Mediterranean (≤3.8%) and G6PD A- vari-
ants (≤2.1%) were low in two studies [63, 64].
Primaquine research on transmission blocking in Africa
PQ research in Africa is limited. Studies have included
G6PDd and G6PD normal healthy individuals, malaria
patients and asymptomatic P. falciparum carriers – all
with high baseline Hb concentrations, usually ≥8 g/dL.
G6PD status has been assessed by the qualitative fluores-
cent spot test or a qualitative rapid diagnostic test, sup-
plemented by genotypic analysis in some studies.
G6PDd and G6PD normal healthy individuals
One MDA study examined 0.75 mg/kg of PQ base, ad-
ministered on D2, in Tanzanian children aged <12 years
(Hb ≥ 8 g/dL) who also received a standard dose of SP
[40]. On D7, genotypically determined homozygous or
hemizygous G6PDd children had the greatest fall in
mean Hb: -2.5 (95% CI -1.2 to -3.8) g/dL vs. -1.6 (-0.9 to
-2.2) g/dL in heterozygous females, and vs. -0.5 (-0.4 to
-0.6) g/dL in G6PD normal children. No PQ PK analysis
was performed but the authors noted that children aged
<5 years were at risk of a greater fall in Hb, independent
of G6PD status, if they received higher mg/kg doses of
PQ. Indeed, an examination of the PQ-dosing regimen
used shows that many children received doses far greater
than the 0.75 mg/kg target dose, based on anthropomet-
ric data of the local population (Table 1) and those of
our modelled database (Table 2).
G6PDd and/or G6PD normal malaria patients
The Tanzanian study of Mwaiswelo et al. [13] showed
that predominantly older children (median age 10 years,
range 1 − 84) whose mean Hb was ~11 g/dL tolerated
SLDPQ (0.25 mg/kg) well when given on D0 with the first
dose of AL. The G6PDd heterozygous females (n = 4) in
the AL-alone arm had the greatest mean absolute decline
in Hb of ~1.7 g/dL whereas the G6PDd hemizygous males
(n = 9) and homozygous females (n = 5) in the AL +
SLDPQ arm had the greatest fall in Hb, a mean of ~1.5 g/
dL with an upper 95% CI of ~2.4 g/dL, representing frac-
tional falls from baseline of 12.6 and 19%, respectively.
The corresponding data for these patients in the AL-alone
group are 0.35 and 1.1 g/dL, and 2.7 and 9.7%.
In G6PD normal patients aged 1–10 years (Hb ≥ 8 g/
dL), AL alone or combined with PQ (0.1, 0.4 or
0.75 mg/kg on D2) resulted in mean falls in Hb on D3
(the nadir in this study) of ~ -0.5 to ~ -0.75 g/dL that
were unrelated to PQ dose. Indeed, the mean changes in
Hb on D2 before PQ was given were very similar and
explain most of the decline in Hb change post-PQ treat-
ment [39]. On further analysis, these authors reported a
PQ dose effect in the mean absolute fall in Hb on D7
(not seen on D3 or D10) in the small number of geno-
typically determined heterozygous females (n = 14) who
received 0.75 mg/kg of PQ compared to those who re-
ceived placebo [65]. The difference in the 0.75 vs. pla-
cebo arm was ~ -0.67 g/dL (p = 0.044).
When P. falciparum-infected children (3–15 years)
were dosed on D3 with 0.75 mg base/kg of PQ, four
G6PDd hemizygous males showed an increasing trend of
a higher decline (median ~ -22%) in the fractional Hb on
D7 compared to the 39 G6PD normal and nine G6PDd
heterozygous females, who had median Hb falls of ~ -5%
[66].
G6PD normal P. falciparum carriers
Goncalves et al. recruited children aged 2− 15 years (Hb ≥
8 g/dL) and reported small changes in mean Hb concentra-
tions on D3 and D7 using AL alone or AL plus 0.25 or
0.4 mg/kg of PQ on D2 [36]. The absolute mean maximal
fall in Hb (measured at the time of maximum fall) was high-
est in the 0.4-mg/kg arm but this was significantly different
Taylor et al. BMC Medicine  (2018) 16:11 Page 4 of 14
(p= 0.006) only when compared to placebo: -1.21 (95% CI
-1.45 to -0.97) vs. -0.71 (-0.98 to -0.44). The proportion of
patients with Hb falls ≥2 g/dL were broadly similar (p= 0.5)
between the AL alone [9/62 (14.5%)], and the AL plus 0.25-
mg/kg [12/75 (16%)] or 0.4-mg/kg PQ [14/73 (19.2%)] arms.
Okebe et al. also reported low and transient mean de-
clines in Hb concentrations at D7 in just over half of
treated asymptomatic P. falciparum carriers (DHAPP
alone and DHAPP plus three PQ doses). The highest
mean decline in Hb occurred on D3 and most subjects
recovered their Hb concentration by D10 [37].
Unpublished G6PDd healthy individuals and P. falciparum
carriers – SAFEPRIM and PQSAFETY studies
Three studies have assessed the tolerability of SLDPQ in
G6PDd males (determined by the fluorescent spot test)
aged 18–45 years with asymptomatic P. falciparum in-
fection (Burkina Faso, n = 50) or healthy volunteers aged
≥10 years (The Gambia, n = 50), who had baseline Hb
concentrations ≥11 g/dL and were treated with either
AL (Burkina Faso, SAFEPRIM I) or DHAPP (The
Gambia, SAFEPRIM II). The PQ doses (0.25 and
0.4 mg/kg) used were tolerated well and the falls in Hb
were generally small when assessed at D7 (U.
D’Alessandro, personal communication). The Hb dy-
namics were characterised by an initial decline in mean
Hb followed by recovery, a pattern similar to that in pa-
tients with acute uncomplicated falciparum malaria.
In a small PQ PK study (ClinicalTrials.gov identifier
NCT02535767) of healthy G6PDd Malian adults with
Hb concentrations ≥10 g/dL, PQ doses of 0.4, 0.45 and
0.5 mg/kg were also tolerated well (I. Chen, personal
communication), with overlap of the fractional and abso-
lute falls in Hb in the G6PD normal and G6PDd groups
given 0.5 mg base/kg of SLDPQ.
Summary of PQ research in Africa
These studies, in which individuals had relatively high
pre-treatment Hb concentrations, have provided useful
data on Hb dynamics in patients of all ages as well as
healthy G6PD normal and G6PDd P. falciparum carriers.
The declines in Hb appeared well tolerated despite falls
≥2 g/dL in some patients. These data show that the de-
clines in Hb in PQ-treated hemizygous males and homo-
zygous females overlap with heterozygous females and
normal individuals who do not receive PQ but that the
distribution in the decline of Hb shifts to the left, i.e. PQ
induces greater absolute and fractional falls in Hb. The
Table 1 The primaquine (PQ) regimen administered to Tanzanian children aged <12 years by Shekalaghe et al. [40] and the mg/kg
they received based on anthropometric data of the local population
Weight (kg) PQ received (mg/kg body weight)*
PQ dose (mg base) Age (years) 25th Median 75th 25th Median 75th
7.5 1–2 9.5 11.0 11.6 0.65 0.68 0.79
15 3–4 11.5 12.9 14.5 1.03 1.16 1.30
15 5–7 14.8 16.7 19.0 0.79 0.90 1.01
22.5 8–11 20.5 23.0 27.1 0.83 0.98 1.10
PQ primaquine
* Corresponding mg base/kg doses of PQ are shown for the 25th, 50th (median) and 75th centiles
Table 2 Calculated mg/kg of primaquine (PQ) base that would be received by children aged <12 years using the PQ regimen of
Shekalaghe et al. [40] based on anthropometric data of the modelled database
Modelled weights (kg)
Age band (years) Minimum 1st 5th 10th 25th Median 75th 90th 95th 99th Maximum
1–2 5.5 6.5 7.4 7.9 8.9 10.0 11.5 12.8 13.6 15.2 18.2
3–4 7.8 9.2 10.4 11.1 12.4 13.8 15.3 16.8 17.9 19.9 23.9
5–7 10.0 11.5 13.0 14.0 15.2 17.0 19.2 21.0 22.8 26.0 32.1
8–11 14.7 16.6 18.4 19.5 21.5 24.0 27.4 31.0 33.2 38.0 46.0
PQ dose (mg base/kg)
PQ dose (mg base) Minimum 1st 5th 10th 25th Median 75th 90th 95th 99th Maximum
7.5 0.41 0.49 0.55 0.59 0.65 0.75 0.84 0.95 1.01 1.15 1.37
15 0.63 0.75 0.84 0.89 0.98 1.09 1.21 1.35 1.44 1.63 1.92
15 0.47 0.58 0.66 0.71 0.78 0.88 0.99 1.07 1.15 1.30 1.50
22.5 0.49 0.59 0.68 0.73 0.82 0.94 1.05 1.15 1.22 1.36 1.53
PQ primaquine
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Hb cost of PQ depends on the dose with a doubling
(from ~10% to ~20%) of the upper 95% CI fractional fall
seen in Tanzanian patients [13], to an approximately six-
fold higher difference in the upper 95% CI of the abso-
lute fall in Hb (3.8 vs. 0.6 g/dL) in the MDA study in
which many children received toxic doses of PQ [40].
The latter study is a salutary reminder of the toxicity
of high mg/kg PQ doses, possibly augmented by sul-
phadoxine, when given to G6PDd A- children [40].
One key group lacking PQ data is young, moderately
anaemic (Hb < 8 g/dL) children with acute uncompli-
cated falciparum malaria.
Background anaemia in African children
In African children, anaemia is common and its aeti-
ology is frequently multifactorial [67]. The rates of back-
ground anaemia in Africa are high (e.g. 40–60%) across
all malaria transmission intensities [68–73], but tend to
be lower in low-transmission settings [69, 72]. Anaemia
is inversely related to age in healthy individuals, asymp-
tomatic falciparum carriers and malaria patients inde-
pendent of malaria transmission intensity [68, 74, 75].
Table 3 shows Hb data in children aged <5 years from a
community survey in the Kenyan highlands (low trans-
mission) [68], and Table 4 shows Hb data in P. falcip-
arum-infected patients of all ages from several African
countries (database used in this analysis).
Younger children would be the prime recipients of
SLDPQ in a programme that targets patients with symp-
tomatic malaria. Although their median Hb concentra-
tions at presentation may seem adequate (Table 4), a
sizeable minority will have moderate anaemia and a
small number will have severe anaemia (Hb < 5 g/dL).
Younger children treated with ACT suffer greater post-
treatment falls in Hb compared to older children. From
our database, children aged <5 years had significantly
lower Hb concentrations at baseline (9.3 vs. 10.9 g/dL)
and D7 (8.6 vs. 10.5 g/dL) compared to children aged 5–
11 years (p values < 0.001).
The risks of P. falciparum-infected children experiencing
PQ-induced AHA and/or clinically significant anaemia
(CSA), including profound anaemia (Hb < 4 g/dL) and se-
vere anaemia (Hb < 5 g/dL) with features of severe malaria,
are unknown. Limited data from a trial comparing ACTs
[42] and a trial comparing SP vs. atovaquone-proguanil
[76] suggest risk factors for a blood transfusion were: (i)
high parasite biomass in ACT-treated children (clinical in-
dication was decompensated anaemia), and, for the SP-
treated children (clinical indications were Hb <3 g/dL or
the development of respiratory distress or extreme leth-
argy), (ii) pre-treatment Hb < 5 g/dL, (iii) younger age, and
(iv) high parasite biomass.
Summary of SLDPQ risk and background anaemia
There are two main reasons to be cautious in setting the
upper dose limit of SLDPQ. Firstly, all the PQ studies
that have recruited G6PDd patients have had high base-
line Hb concentrations; therefore, we cannot extrapolate
with confidence these findings to young symptomatic
anaemic P. falciparum-infected children who have lower
Hb concentrations (Table 4) and, secondly, the initial re-
duction in Hb level in PQ-treated asymptomatic P. fal-
ciparum carriers is similar to uncomplicated falciparum
malaria patients, with some individuals experiencing Hb
drops >2 g/dL [36, 37].
Predicting the fall in Hb in young PQ-treated malaria
patients is challenging, but based on: (i) the published data
cited above, (ii) unpublished summarised post-treatment
Hb dynamics data for African patients aged <5 years
(kindly provided by the WorldWide Antimalarial Resist-
ance Network), (iii) the inverse relationship between base-
line Hb and post-treatment Hb decline, and (iv) avoiding
the tendency to underplay the toxicity of SLDPQ, we hy-
pothesise that an average population of P. falciparum-in-
fected African children aged <5 years may experience Hb
declines of: (i) 1 g/dL (median), (ii) 1.5 g/dL (lower inter-
quartile range), and (iii) 3 g/dL (lower 5%).
On the other hand, Shekalaghe et al. provide some re-
assurance that toxic doses of PQ were tolerated well in
apparently healthy Tanzanian children aged 1–12 years
with Hb concentrations ≥8 g/dL [40]. Moreover, in areas
of low malaria transmission, the rates of background an-
aemia are less, so the risk of SLDPQ-induced AHA
should be less compared to areas of high transmission
and high background rates of anaemia.
We adopted a risk-stratified approach to setting the
dose of SLDPQ. Given the uncertainty of the haemolytic
potential of PQ in very young P. falciparum-infected
Table 3 Haemoglobin concentrations in g/dL in healthy children aged 6 months to 4 years from low-transmission areas in western
Kenya [68], where only 0.3% (5/1697) were polymerase chain reaction (PCR) positive for P. falciparum in the community
Age (years) 1st 5th 10th 25th Median 75th 90th 95th 99th No.
<1 6.1 7.8 8.1 9.3 10.5 11.0 12.0 12.3 13.0 37
1 5.9 6.5 7.3 9.2 10.2 10.9 11.6 12.1 13.3 59
2 5.8 7.7 8.7 9.7 10.5 11.3 12.7 13.0 14.0 73
3 6.8 8.4 9.1 9.9 11.4 12.15 12.8 13.2 14.0 80
4 5.3 9 9.7 10.9 12.0 12.7 13.4 13.6 14.8 79
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children aged 6 − 11 months and the need to be cautious,
we decided to under-dose them and arbitrarily set a dose
of 1.25 mg PQ base, for a median PQ dose of 0.16 mg/kg
(i.e. ~60% of the WHO recommendation). For children
aged 1–5 years, we set an upper limit of 0.4 mg/kg of PQ
base but increased this upper limit to 0.5 mg/kg for older
children because they have less post-treatment declines in
Hb and appear to tolerate SLDPQ well.
Methods
Assembling the African anthropometric database
We obtained permission to download anthropometric
databases from the Demographic Health Survey website
(https://dhsprogram.com/), which include a broad range
of socioeconomic, geographical and other randomly col-
lected data; however, the anthropometric data are con-
fined to girls and boys aged <60 months and women
aged 15 − 45 years. Other databases obtained from aca-
demic researchers, Médecins Sans Frontières, France,
and Epicentre, Paris, contained data from malaria pa-
tients and field surveys of individuals from malaria-
endemic areas.
The first author approached individuals to explain
the purpose of this project and requested anonymised
anthropometric data. Later, haematological data were
also sought. All those who freely gave data would be
co-authors and were expected to provide feedback on
this paper.
Data obtained from KEMRI-WT (Kenya) followed a
formal request to a data access committee. We consid-
ered ethical approval unnecessary for this project, which
was confirmed by the Oxford Tropical Research Ethics
Committee.
Modelling the weight-for-age data
The raw weight-for-age data were modelled into a
growth curve (Additional file 1: Figure S1) by excluding
outlying weight-for-age data, which were defined as
values falling outside the 1st and 99th centiles (as was
done for the Cambodian database). Modelled weight-for-
age centiles were obtained using the three-parameter
Box–Cox power exponential distribution [77] and the
centile growth curves smoothed using the cubic spline
smoothing technique [78]. The modelling was performed
in Stata using the ‘xriml’ macro Stata module [77] with a
cubic spline.
The ages of children aged 6 − 11 months were
expressed as a decimal of 1 year. Ages ≥12 months were
rounded down to whole integers (e.g. 2 years and
5 months was rounded down to 2 years) and ages
≥18 years were grouped together. The mg base/kg dose
of PQ received for a given age group was calculated as
PQ dose/all the weights for that age group.
Table 4 Baseline haemoglobin concentrations in g/dL in patients of both sexes with acute uncomplicated falciparum malaria
enrolled in trials in several African countries
Age (years) 1st 5th 10th 25th Median 75th 90th 95th 99th No.
0.5 to <1 4.8 5.5 6.0 6.9 8.2 9.7 10.7 11.7 12.8 1693
1 4.8 5.9 6.4 7.4 8.9 10.2 11.5 12.1 13.6 3247
2 4.8 5.9 6.7 7.8 9.4 10.7 11.7 12.7 14.0 2262
3 5.0 6.1 7.1 8.6 9.9 11.2 12.4 12.8 14.2 1838
4 5.0 6.3 7.3 8.9 10.2 11.5 12.5 13.2 14.3 1528
5 5.5 7.1 7.5 9.1 10.5 11.8 12.8 13.3 14.1 602
6 5.5 7.1 7.6 9.0 10.3 11.6 12.6 13 14.3 429
7 5.0 7.1 7.8 9.3 10.6 11.9 13.0 13.8 15.1 357
8 5.1 6.8 7.7 9.4 10.9 12.1 13.2 14.0 15.5 297
9 6.3 7.5 8.6 9.7 11.0 12.5 13.2 13.6 14.8 232
10 6.7 7.7 8.9 10.1 11.3 12.7 13.8 14.2 15.1 227
11 6.8 7.4 8.9 10 11.6 12.7 14.0 14.8 15.5 133
12 6.4 8.2 9.4 10.5 11.6 12.9 14.0 14.8 15.8 100
13 6.5 7.8 8.5 10.1 11.5 12.6 14.0 15.1 15.4 57
14 7.1 7.9 9.2 10.4 11.6 12.8 13.7 14.3 15.5 62
15 7.8 8.0 9.0 9.7 11.1 12.5 14.4 15.2 15.6 33
16 8.0 8.4 9.2 10.5 12.0 13.5 14.7 16.1 17.3 33
17 7.8 7.8 8.6 10.2 12.0 13.6 15.8 15.9 16.1 24
≥18 6.7 8.2 9.1 10.9 12.3 13.9 15.1 16 17.3 574
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Data analysis and determining optimal age-dosing
categories
Within each age-dosing group, we calculated the propor-
tions of males and females who would receive thera-
peutic doses for a given age in years as well as for the
age-dosing group overall. Male–female differences were
compared by Fisher’s exact test, differences in the distri-
bution of skewed data were compared using Mann
Whitney U test and mean differences in normally dis-
tributed data were compared using an unpaired t-test. A
p value ≤0.05 was considered significant.
PQ doses of 1–15 mg were tested across different age
groups and the results analysed. The final age categories
were selected based on: (i) the need to be especially cau-
tious in children aged 6 − 11 months, (ii) the mg base/kg
dose received, (iii) the proportions receiving a therapeutic
dose, (iv) how well a given dosing band fitted in with the
next dosing band, and (v) a desire to minimise the number
of dosing groups and to use the same tablet strengths as
those in the Cambodian regimen (i.e. 2.5, 5, 7.5 and 15 mg
of PQ base).
Results
Features of the anthropometric database
The modelled database numbered 661,979 individuals
aged ≥6 months. The female/male ratio is 2:1 [missing
data = 95 (0.01%)] and the rural/urban ratio is 2.6:1. In-
dividuals aged 6–11 months, 1 − 4 years, 5–14 years and
≥15 years represent approximately 6%, 38%, 6% and 50%
of the database. The Demographic Health Survey data
accounted for 83.0% (n = 549,127) of the database whilst
malaria (n = 28,466), other infections (n = 30,009) and
miscellaneous data from rural clinics (n = 54,377)
accounted for 4.3%, 4.5%, and 8.2%, respectively. The
distributions of these categories by countries are shown
in Additional file 2: Table S1. The weight distributions in
children aged ≤5 years with and without malaria over-
lapped substantially (Fig. 1).
Dosing regimen
There are five age-dosing groups (Table 5). Overall, the
model predicts that ~94–99% of patients in dosing
bands from 1 year upwards would receive a PQ dose
within the defined therapeutic range, and that their me-
dian doses would range from 0.23 to 0.29 mg/kg of PQ
base. The median dose for children aged 6–11 months is
0.16 mg/kg. Based on our minimally efficacious
transmission-blocking dose of 0.15 mg/kg PQ, 27% of
infants will be under-dosed but this falls to 3.3% (1,322/
39,886) if using the minimum dose of 0.125 mg/kg of
PQ base, as reported by Dicko et al.
Primaquine dose breakdown by individual ages and sex
The proportions of females and males predicted to
receive subtherapeutic, supratherapeutic and thera-
peutic doses are shown in Figs. 2 and 3, respectively.
Rates of supratherapeutic dosing are low, a maximum
of 1.3% in females aged 1 year. Age groups at risk of
under-dosing exceeding 5% are females and males
aged 6 to <12 months, 4 and 5 years, and females
aged 14 years. Altogether, 73.5% to 100% of females
(Fig. 2) and 67.5% to 100% of males (Fig. 3) would
receive a therapeutic dose.
The median mg base/kg dose of PQ base ranged from
0.17 to 0.32 in females (Fig. 4) and from 0.17 to 0.33 in
males (Fig. 5). The age groups with the lowest median
5
10
15
20
25
5
10
15
20
25
Community illnesses Malaria patients
Other infections Survey data
Fig. 1 Box plots of modelled weights in children aged less than five years by health status
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mg/kg dose were 6–11 months, 4 years, and 5 years
(0.17), and 3 years and 14 years (0.19) for females, and
6–11 months and 5 years (0.16), 4 years (0.17), and
3 years (0.19) for males.
Discussion
This age-dosing SLDPQ regimen for SSA was developed
from an anthropometric database of more than 660,000
individuals from across the continent. It has five dosing
groups and how optimised they are will be tested in a
large randomised trial to assess its safety in G6PDd and
G6PD normal African children with acute uncompli-
cated falciparum malaria (ISRCTN11594437). If this trial
shows acceptable safety and adequate PK profiles, it will
provide substantial reassurance to African ministries of
health in accelerating the uptake of SLDPQ.
These data overlapped substantially with data from mal-
aria patients and other survey data conducted in predom-
inantly rural areas. Thus, our database is representative of
target populations for SLDPQ. Although the WHO cur-
rently recommends that SLDPQ be used in symptomatic
malaria patients, it is likely to be used as an elimination
tool in asymptomatic parasite carriers, who contribute
substantially to malaria transmission [79].
Setting the upper therapeutic range of PQ is crucial for
safety and challenging in the absence of a robust dose–re-
sponse relationship of PQ PK and Hb decline. In contrast
to our approach for Cambodia, where malaria is mostly a
disease of adults and where background rates of anaemia
and malaria-related anaemia are lower [18], we placed
much emphasis on the risk of young paediatric patients
developing CSA following ACT + PQ because they have
lower pre-treatment Hb concentrations and greater falls
in Hb, and so a higher risk of CSA compared to older chil-
dren. In addition, two studies support high parasite bio-
mass as another risk factor for CSA [42, 76].
Therefore, we decided to be cautious and deliberately
under-dose infants with 1.25 mg of PQ base, resulting in a
mg/kg dose range of 0.1–0.3 (median of 0.16). In this sce-
nario, ~60% of infants would receive less than the WHO-
recommended PQ dose of 0.25 mg/kg. What effect this
would have on mosquito infectivity is unknown and more re-
search is needed to establish the dose–response (i.e. PQ PK–
infectivity) relationship and refine the minimum PQ dose.
We set a minimum PQ dose of 0.15 mg/kg, based on
data from the field experience of MDA in Cambodia
[80], which is higher than the 0.125 mg/kg suggested by
Dicko et al. in their mosquito infectivity experiments
Table 5 The proposed age-based dosing regimen showing the proportions of individuals who would receive a subtherapeutic,
therapeutic or supratherapeutic dose and the corresponding mg base/kg doses of primaquine (PQ)
PQ dose
(mg base)
Subtherapeutic
dose <0.15 mg/kg, n (%)
Therapeutic dose
0.15–0.5 mg/kg, n (%)
Supratherapeutic
dose >0.5 mg/kg, n (%)
Modelled weights
by centile (kg)
PQ dose by centile
(mg base/kg)
1st Median 99th 1st Median 99th
0.5 to <1
(n = 39,886)
1.25 10,778 (27.0) 29,180 (73.2) 0 5.0 7.6 10.8 0.12 0.16 0.25
1–5 (n = 261,036) 2.5 15,744 (6.0) 244,537 (93.7) 755 (0.3) 6.8 12.0 19.2 0.13 0.21 0.37
6–9 (n = 20,770) 5 80 (0.4) 20,690 (99.6) 0 13.2 20.0 31.2 0.16 0.25 0.38
10–14 (n = 12,155) 7.5 69 (0.6) 12,086 (99.4) 0 20.0 29.0 49.0 0.15 0.26 0.38
≥15 (n = 328,132) 15 469 (0.14) 327,620 (99.8) 43 (0.01) 37.8 55.3 90.2 0.17 0.27 0.40
PQ primaquine
Fig. 2 Histogram showing the proportions of females who would
receive a subtherapeutic, therapeutic or supratherapeutic dose
of primaquine
Fig. 3 Histogram showing the proportions of males who would
receive a subtherapeutic, therapeutic or supratherapeutic dose
of primaquine
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[81]. Which of the two is the more accurate value is un-
known. Our threshold predicts ~25% under-dose rate in
infants compared to 3% if we use the threshold of Dicko
et al. This emphasises the need to define accurately the
minimum transmission-blocking dose and to consider
how much of a transmission reservoir such young
children represent and, therefore, the need to give them
SLDPQ.
Much emphasis and anxiety have been placed on the
potential dangers of PQ-induced AHA in treated P.
falciparum-infected G6PDd individuals but there are
many other factors that may play an important role in
post-treatment Hb dynamics and the risk of post-
treatment CSA, such as sickle-cell trait/disease, alpha-
thalassaemia, HIV infection, hookworm infection, vita-
min A deficiency, poor nutritional state, schistosomiasis,
baseline parasitaemia and Hb, and PQ PK [42, 67, 73,
76, 82].
Insights will be forthcoming from our safety trial of
SLDPQ and from the large multicentre TRACT study
(Transfusion and treatment of severe anaemia in African
children trial [83]), which is designed to address optimal
blood transfusion strategies in children admitted to hos-
pital with Hb ≤6 g/dL. Data from both trials will inform
strategies aimed at identifying children at risk of CSA
before they are treated with ACT + SLDPQ and how this
may be best achieved in challenging settings, e.g. small
remote clinics that may not have accurate point-of-care
tests to measure Hb concentration or the time or means
to quantify parasitaemias.
Another key safety issue is the haemolytic effect of
SLDPQ in individuals carrying the severe G6PDd
Santamaria and Mediterranean variants. Limited data
in P. falciparum-infected Cambodians with G6PDd
Viangchan (median G6PD activity 0.8 U/g Hb [17, 46])
are encouraging, but are only partially applicable to
Fig. 4 The mg base/kg dose of primaquine (PQ) by centile that females would receive as a function of age. The proposed therapeutic range of
PQ base in mg/kg body weight is 0.15–0.4 (1–5 years) to 0.5 (≥6 years). PQ primaquine
Fig. 5 The mg base/kg dose of primaquine (PQ) base by centile that males would receive as a function of age. The proposed therapeutic range
of PQ base in mg/kg body weight is 0.15–0.4 (1–5 years) to 0.5 (≥6 years). PQ primaquine
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Africa. Fractional declines in Hb on D7 overlapped in
G6PDd and G6PD normal patients (mostly adults)
who were treated with DHAPP + SLDPQ or DHAPP
alone (L. Desoley, unpublished data). One reassuring
aspect of our age-based regimen is that we have re-
stricted the upper limits of PQ and the proportions
of individuals receiving supratherapeutic doses is very
small, <1.4% in those aged 1 or 15 years.
Our SLDPQ regimen has five dosing bands and the
first (6–11 months) has the most restricted age limits.
Anecdotally, concern is expressed that age-based dosing
is intrinsically inaccurate because patients or guardians
are unable to report ages accurately and birth certificates
or ‘Road to Health’ cards may not be widely available in
some areas. This was not an issue in the MDA of ASAQ
during the Ebola outbreak in which 98% (983/1005) of
individuals or guardians in Monrovia were able to tell
their ages and take the correct dose of ASAQ [20].
Nevertheless, this is an aspect that needs to be consid-
ered when SLDPQ is deployed.
This SLDPQ regimen shares the same tablet
strengths (aside from the 6–11 months age band) as
the one designed for Cambodia [16]. This overlap in
regimens between Africa and Cambodia (and by ex-
tension the Greater Mekong Subregion) may reassure
the pharmaceutical industry regarding the market for
SLDPQ. Indeed, the 2012 WHO recommendation was
global. Moreover, if the same table strengths could be
used in regimens for P. vivax radical cure, this should
stimulate the pharmaceutical industry to produce 2.5-
and 5-mg tablet strengths and paediatric formulations.
This would have a positive effect on access. Substan-
tial evidence on the safety of SLDPQ should be forth-
coming in the next 2 years from our trial and other
studies, and should allay anxieties that pharmaceutical
companies may have regarding PQ toxicity and their
liability.
Our analysis has limitations. Similar to others [19, 84],
our database was dominated by children aged <5 years
and women of childbearing age because most data from
the Demographic Health Survey and malaria patients,
especially in SSA, are from these groups. Although chil-
dren aged 5–17 years represented 12% of the total data-
base, each individual age group contained >2500
individuals (except ages 13 and 14 years).
The dosing regimen is not generalisable to countries
outside of SSA and, like the Cambodian regimen, does
not dovetail nicely with the age–weight dosing categor-
ies of commonly used ACTs. DHAPP has eight weight-
based dosing bands with an emphasis on children who
weigh <25 kg to ensure they receive sufficient dihy-
droartemisinin. AL, currently the most widely used
ACT in Africa, has four weight-based dosing bands and
ASAQ has four age-based bands (2–11 months, 1–5
years, 6–13 years and ≥14 years) that share two of the
five age-based bands of our SLDPQ regimen. Suitable
training would be essential before SLDPQ is imple-
mented by programmes.
We designed this SLDPQ regimen based on current
but incomplete knowledge, especially PQ PK in
young children. Goncalves et al. have contributed
useful data in asymptomatic falciparum carriers [26]
and we hope to close the PK gap further. With this
new knowledge and, possibly, the eventual definition
of the dose–response relationship between PQ’s oxi-
dative metabolites and haemolysis and mosquito in-
fectivity, our proposed SLDPQ regimen may need to
be amended.
Conclusions
This age-based regimen of SLDPQ was designed to
block P. falciparum transmission in SSA and will be
tested for safety in a large trial in Uganda and the
Democratic Republic of Congo in 2017. Depending on
the results, this dose regimen may require fine-tuning
but could also be readily adopted by national malaria
control programmes.
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